Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 20-Sep-24 4:15 PM View:  | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 19-Sep-24 | Option Exercise | 22,831 | $4.38 | $99,999.80 | 8% 286.38K to 309.21K | |
| 17-Sep-24 8:05 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 16-Sep-24 | Market Sale | 30,000 | $12.97 | $389,100.00 | (9%) 316.38K to 286.38K | (10%) |
| 17-Sep-24 8:05 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 13-Sep-24 | Market Sale | 65,000 | $13.47 | $875,550.00 | (17%) 381.38K to 316.38K | (6%) |
| 30-Aug-24 4:15 PM View: | Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 28-Aug-24 | Option Exercise | 50,000 | $4.38 | $219,000.00 | 62% 81.26K to 131.26K | |
| 30-Aug-24 4:15 PM View: | Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 28-Aug-24 | Option Sale | 50,000 | $15.37 | $768,500.00 | (38%) 131.26K to 81.26K | |
| 27-Aug-24 5:05 PM View: | Wilms Joris SVP & CHIEF OPERATING OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 26-Aug-24 | Market Sale | 5,000 | $14.69 | $73,450.00 | (14%) 35.6K to 30.6K | 2% |
| 12-Jul-24 5:29 PM View: | Pfreundschuh Peter P. CFO and Treasurer | Y-Mabs Therapeutics, Inc. (YMAB) | 12-Jul-24 | Grant | 46,000 | -- | -- | 100% 0 to 46.0K | |
| 13-Jun-24 9:02 PM View: | Hamill Laura Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Jun-24 | Grant | 3,495 | -- | -- | 150% 2.33K to 5.83K | |
| 11-Jun-24 7:53 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Jun-24 | Sale | 35,000 | $12.00 | $420,000.00 | (8%) 416.38K to 381.38K | |
| 13-Jun-24 9:00 PM View: | Tyagi Ashu Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Jun-24 | Grant | 3,495 | -- | -- | 150% 2.33K to 5.83K | |
| 13-Jun-24 9:01 PM View: | Healy James Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Jun-24 | Grant | 3,495 | -- | -- | < 1% 2.22M to 2.23M | |
| 13-Jun-24 9:02 PM View: | Tagliaferri Mary Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Jun-24 | Grant | 3,495 | -- | -- | 75% 4.66K to 8.15K | |
| 13-Jun-24 9:00 PM View: | Gill David N Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Jun-24 | Grant | 3,495 | -- | -- | 150% 2.33K to 5.83K | |
| 13-Jun-24 9:01 PM View: | Wedell-Wedellsborg Johan Director 10% Owner | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Jun-24 | Grant | 3,495 | -- | -- | < 1% 4.56M to 4.57M | |
| 11-Jun-24 7:53 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 10-Jun-24 | Sale | 35,000 | $12.03 | $421,050.00 | (8%) 451.38K to 416.38K | |
| 11-Jun-24 7:54 PM View: | Ber Gerard Director | Y-Mabs Therapeutics, Inc. (YMAB) | 10-Jun-24 | Sale | 722 | $12.00 | $8,664.00 | (31%) 2.33K to 1.61K | |
| 31-May-24 9:36 PM View: | Kruse Bo EVP, CFO, Secry & Treas. | Y-Mabs Therapeutics, Inc. (YMAB) | 31-May-24 | Option Sale | 31,371 | $12.07 | $378,648.00 | (13%) 242.25K to 210.88K | |
| 31-May-24 9:36 PM View: | Kruse Bo EVP, CFO, Secry & Treas. | Y-Mabs Therapeutics, Inc. (YMAB) | 31-May-24 | Option Exercise | 31,371 | $2.00 | $62,742.00 | 15% 210.88K to 242.25K | |
| 31-May-24 9:36 PM View: | Kruse Bo EVP, CFO, Secry & Treas. | Y-Mabs Therapeutics, Inc. (YMAB) | 30-May-24 | Option Sale | 28,629 | $12.03 | $344,407.00 | (12%) 239.51K to 210.88K | |
| 31-May-24 9:36 PM View: | Kruse Bo EVP, CFO, Secry & Treas. | Y-Mabs Therapeutics, Inc. (YMAB) | 30-May-24 | Option Exercise | 28,629 | $2.00 | $57,258.00 | 14% 210.88K to 239.51K | |
| 23-May-24 10:00 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 23-May-24 | Sale | 7,351 | $13.00 | $95,563.00 | (2%) 458.73K to 451.38K | |
| 23-May-24 10:00 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 21-May-24 | Sale | 25,000 | $12.00 | $300,000.00 | (5%) 483.73K to 458.73K | |
| 14-Mar-24 5:01 PM View: | Tagliaferri Mary Director | Y-Mabs Therapeutics, Inc. (YMAB) | 12-Mar-24 | Grant | 4,660 | -- | -- | 100% 0 to 4.66K | |
| 07-Mar-24 4:59 PM View: | Smith Susan Laura SVP & CHIEF COMMERCIAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 05-Mar-24 | Private Sale | 1,682 | $16.55 | $27,837.10 | (5%) 35.6K to 33.92K | |
| 07-Mar-24 5:02 PM View: | Rajah Vignesh SVP & CHIEF MEDICAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 05-Mar-24 | Private Sale | 1,711 | $16.53 | $28,282.80 | (4%) 39.87K to 38.16K | |
| 07-Mar-24 5:01 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 05-Mar-24 | Private Sale | 3,900 | $16.44 | $64,116.00 | (< 1%) 487.63K to 483.73K | |
| 14-Feb-24 4:30 PM View: | Rossi Michael J President & CEO Director | Y-Mabs Therapeutics, Inc. (YMAB) | 12-Feb-24 | Grant | 35,700 | -- | -- | 100% 0 to 35.7K | |
| 22-Jan-24 6:00 PM View: | Smith Susan Laura SVP & CHIEF COMMERCIAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 17,800 | -- | -- | 100% 17.8K to 35.6K | |
| 22-Jan-24 5:54 PM View: | Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 17,800 | -- | -- | 28% 63.46K to 81.26K | |
| 22-Jan-24 5:48 PM View: | Kruse Bo EVP, CFO, Secry & Treas. | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 18,100 | -- | -- | 9% 192.78K to 210.88K | |
| 22-Jan-24 5:56 PM View: | Wilms Joris SVP & CHIEF OPERATING OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 17,800 | -- | -- | 100% 17.8K to 35.6K | |
| 22-Jan-24 5:58 PM View: | Lisby Steen SVP & CHIEF SCIENTIFIC OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 17,800 | -- | -- | 100% 17.8K to 35.6K | |
| 22-Jan-24 6:02 PM View: | Rajah Vignesh SVP & CHIEF MEDICAL OFFICER | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 17,800 | -- | -- | 81% 22.07K to 39.87K | |
| 22-Jan-24 5:52 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 18-Jan-24 | Grant | 22,100 | -- | -- | 5% 465.53K to 487.63K | |
| 26-Dec-23 4:15 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 21-Dec-23 | Option Exercise | 50,000 | $2.00 | $100,000.00 | 12% 415.53K to 465.53K | |
| 15-Dec-23 7:40 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 15-Dec-23 | Sale | 50,000 | $6.61 | $330,500.00 | (11%) 465.53K to 415.53K | |
| 15-Dec-23 7:40 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 14-Dec-23 | Sale | 50,000 | $6.83 | $341,500.00 | (10%) 515.53K to 465.53K | |
| 15-Dec-23 7:40 PM View: | Gad Thomas Chief Business Officer Director | Y-Mabs Therapeutics, Inc. (YMAB) | 13-Dec-23 | Sale | 50,000 | $6.58 | $329,000.00 | (9%) 565.53K to 515.53K | |
| 11-Dec-23 5:25 PM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Dec-23 | Purchase Duplicate | 102,863 | $7.01 | $720,843.00 | 2% 4.45M to 4.55M | |
| 11-Dec-23 5:25 PM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Dec-23 | Purchase | 102,863 | $7.01 | $720,843.00 | 2% 4.45M to 4.55M | |
| 12-Dec-23 8:26 AM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Dec-23 | Private Purchase Duplicate | 6,455 | $6.85 | $44,231.60 | < 1% 4.55M to 4.56M | |
| 12-Dec-23 8:27 AM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 11-Dec-23 | Private Purchase | 6,455 | $6.85 | $44,231.60 | < 1% 4.55M to 4.56M | |
| 11-Dec-23 5:25 PM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 08-Dec-23 | Purchase | 18,503 | $6.99 | $129,379.00 | < 1% 4.43M to 4.45M | |
| 11-Dec-23 5:25 PM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 08-Dec-23 | Purchase Duplicate | 18,503 | $6.99 | $129,379.00 | < 1% 4.43M to 4.45M | |
| 11-Dec-23 5:25 PM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 07-Dec-23 | Private Purchase Duplicate | 6,183 | $6.50 | $40,189.50 | < 1% 4.43M to 4.43M | |
| 11-Dec-23 5:25 PM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 07-Dec-23 | Private Purchase | 6,183 | $6.50 | $40,189.50 | < 1% 4.43M to 4.43M | |
| 01-Dec-23 5:14 PM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 29-Nov-23 | Private Purchase Duplicate | 51,837 | $5.97 | $309,477.00 | 1% 4.37M to 4.43M | |
| 01-Dec-23 5:15 PM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 29-Nov-23 | Private Purchase | 51,837 | $5.97 | $309,477.00 | 1% 4.37M to 4.43M | |
| 29-Nov-23 5:14 PM View: | Wg Biotech Aps Director | Y-Mabs Therapeutics, Inc. (YMAB) | 28-Nov-23 | Purchase | 30,671 | $5.81 | $178,275.00 | < 1% 4.34M to 4.37M | |
| 29-Nov-23 5:15 PM View: | Wedell-Wedellsborg Johan Director | Y-Mabs Therapeutics, Inc. (YMAB) | 28-Nov-23 | Purchase Duplicate | 30,671 | $5.81 | $178,275.00 | < 1% 4.34M to 4.37M |
